Skip to main content

Advertisement

SpringerLink
Log in

Percutaneous radiofrequency ablation for patients with malignant lung tumors: a phase II prospective multicenter study (JIVROSG-0702)

  • Original Article
  • Published:
Japanese Journal of Radiology Aims and scope Submit manuscript

Abstract

Purpose

This prospective multicenter study aimed to evaluate the efficacy and safety of percutaneous radiofrequency (RF) ablation for lung cancer.

Materials and methods

From May 2008 to April 2012, 33 patients (26 men, 7 women; mean age 70.5 years) were enrolled. RF ablation was performed using an internally cooled or expandable multitined electrode. The primary endpoint was complete response (CR) determined using 18F fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) performed 6 months after RF ablation. The secondary endpoint was the incidence and grade of adverse events (AEs) evaluated using the Common Toxicity Criteria for Adverse Events, version 3.0.

Results

All patients underwent RF ablation and had efficacy analyses evaluated; however, FDG-PET/CT images before RF ablation were not available for two patients. The CR rate was 68 % (21 of 31 patients). One patient had a grade 5 AE unrelated to RF ablation. Grade ≥3 AEs occurred in 12 % of patients. During the follow-up period (median 37 months; range 1–55 months), five patients developed local tumor progression and nine (29 %) died. Overall survival at 1, 2, and 3 years was 97, 82, and 74 %, respectively.

Conclusion

Percutaneous RF ablation is a safe, feasible, and effective treatment for small malignant lung tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. National Cancer Center. Cancer statistics in Japan. 2015. http://www.ncc.go.jp/en/index.html. Accessed Nov 27, 2015.

  2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–17.

    Article  PubMed  Google Scholar 

  3. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2.

    Article  PubMed  PubMed Central  Google Scholar 

  4. European Association for the Study of the Liver. European Organisation for Research and Treatment of Cancer EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.

    Article  Google Scholar 

  5. de Baère T, Palussière J, Aupèrin A, Hakime A, Abdel-Rehim M, Kind M, et al. Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation. Radiology. 2006;240:587–96.

    Article  PubMed  Google Scholar 

  6. Gillams AR, Lees WR. Radiofrequency ablation of lung metastases: factors influencing success. Eur Radiol. 2008;18:672–7.

    Article  PubMed  Google Scholar 

  7. Hiraki T, Sakurai J, Tsuda T, Gobara H, Sano Y, Mukai T, et al. Risk factors for local progression after percutaneous radiofrequency ablation of lung tumors: evaluation based on a preliminary review of 342 tumors. Cancer. 2006;107:2873–80.

    Article  PubMed  Google Scholar 

  8. Lencioni R, Crocetti L, Cioni R, Suh R, Glenn D, Regge D, et al. Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicenter clinical trial (the RAPTURE study). Lancet Oncol. 2008;9:621–8.

    Article  PubMed  Google Scholar 

  9. Chua TC, Sarkar A, Saxena A, Glenn D, Zhao J, Morris DL. Long-term outcome of image-guided percutaneous radiofrequency ablation of lung metastases: an open-labeled prospective trial of 148 patients. Ann Oncol. 2010;21:2017–22.

    Article  CAS  PubMed  Google Scholar 

  10. Dupuy DE, Fernando HC, Hllman S, Ng T, Tan AD, Sharma A, Rilling WS, Hong Kelvin, Putnam JB. Radiofrequency ablation of stage IA non-small cell lung cancer in medically inoperable patients: results from the American College of Surgeons Oncology Group Z4033 (Alliance) trial. Cancer. 2015;121:3491–8.

  11. Higuchi M, Honjo H, Shigihara T, Shishido F, Suzuki H, Gotoh M. A phase II study of radiofrequency ablation therapy for thoracic malignancies with evaluation by FDG-PET. J Cancer Res Clin Oncol. 2014;140:1957–63.

    Article  CAS  PubMed  Google Scholar 

  12. Japan Clinical Oncology Group (JCOG). Common terminology criteria for adverse events version 3.0. 2007. http://www.jcog.jp/doctor/tool/ctcae.html. Accessed Nov 27, 2015.

  13. Okuma T, Okamura T, Matsuoka T, Yamamoto A, Oyama Y, Toyoshima M, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for assessment of patients with unresectable recurrent or metastatic lung cancers after CT-guided radiofrequency ablation: preliminary results. Ann Nucl Med. 2006;20:115–21.

    Article  PubMed  Google Scholar 

  14. Higaki F, Okumura Y, Sato S, Hiraki T, Gobara H, Akaki S, et al. Preliminary retrospective investigation of FDG-PET/CT timing in follow-up of ablated lung tumor. Ann Nucl Med. 2008;22:157–63.

    Article  PubMed  Google Scholar 

  15. Bonichon F, Palussière J, Godbert Y, Pulido M, Descat E, Devillers A, et al. Diagnostic accuracy of 18F-FDG PT/CT for assessing response to radiofrequency ablation treatment in lung metastases: a multicenter prospective study. Eur J Nucl Mol Imaging. 2013;40:1817–27.

    Article  CAS  Google Scholar 

  16. Deandreis D, Leboulleux S, Dromain C, Auperin A, Coulot J, Lumbroso J, et al. Role of FDG-PET/CT and chest CT in the follow-up of lung lesions treated with radiofrequency ablation. Radiology. 2011;258:270–6.

    Article  PubMed  Google Scholar 

  17. Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med. 2009;50(Suppl 1):11S–20S.

    Article  CAS  PubMed  Google Scholar 

  18. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49:480–508.

    Article  PubMed  Google Scholar 

  19. Hiraki T, Tajiri N, Mimura H, Yasui K, Gobara H, Mukai T, et al. Pneumothorax, pleural effusion, and chest tube placement after radiofrequency ablation of lung tumors: incidence and risk factors. Radiology. 2006;241:275–83.

    Article  PubMed  Google Scholar 

  20. Yamagami T, Kato T, Hirota T, Yoshimatsu R, Matsumoto T, Nishimura T. Pneumothorax as a complication of percutaneous radiofrequency ablation for lung neoplasms. Diag Interv Radiol. 2006;17:1625–9.

    Article  Google Scholar 

  21. Okuma T, Matsuoka T, Yamamoto A, Oyama Y, Toyoshima M, Nakamura K, et al. Frequency and risk factors of various complications after computed tomography-guided radiofrequency ablation of lung tumors. Cardiovasc Interv Radiol. 2008;31:122–30.

  22. Hiraki T, Gobara H, Fujiwara H, Ishii H, Tomita K, Uka M, et al. Lung cancer ablation: complications. Semin Interv Radiol. 2013;30:169–75.

    Article  Google Scholar 

  23. Steinke K, Sewell PE, Dupuy D, Lencioni R, Helmberger T, Kee ST, et al. Pulmonary radiofrequency ablation—an international study survey. Anticancer Res. 2004;24:339–43.

  24. Kashima M, Yamakado K, Takaki H, Kodama H, Yamada T, Uraki J, et al. Complications after 1000 lung radiofrequency ablation sessions in 420 patients: a single center’s experiences. AJR Am J Roentgenol. 2011;197:W576–80.

    Article  PubMed  Google Scholar 

  25. Tada A, Hiraki T, Iguchi T, Gobara H, Mimura H, Toyooka S, et al. Influence of radiofrequency ablation of lung cancer on pulmonary function. Carciovasc Interv Radiol. 2012;35:860–7.

    Article  Google Scholar 

Download references

Acknowledgments

This study was supported by a Grant-in-Aid for a comprehensive research project on the practical application of medical technology from the Japanese Ministry of Health, Labour, and Welfare.

Author information

Authors and Affiliations

  1. Department of Radiology, Okayama University Medical School, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Japan

    Hideo Gobara, Takayoshi Shinya & Susumu Kanazawa

  2. Department of Diagnostic Radiology, National Cancer Center, Tokyo, Japan

    Yasuaki Arai, Hirokazu Watanabe & Hiroaki Kurihara

  3. Department of Interventional Radiology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan

    Takeshi Kobayashi

  4. Department of Interventional Radiology, Mie University School of Medicine, Tsu, Japan

    Koichiro Yamakado

  5. Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, Nagoya, Japan

    Yoshitaka Inaba

  6. Department of Radiology, Teine Keijinkai Hospital, Sapporo, Japan

    Yoshihisa Kodama

  7. Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan

    Takuji Yamagami

  8. Department of Radiology, Iwate Medical University School of Medicine, Morioka, Japan

    Miyuki Sone

  9. Department of Radiology, Fukuyama City Hospital, Fukuyama, Japan

    Yoshihiro Okumura

Authors
  1. Hideo Gobara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yasuaki Arai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takeshi Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Koichiro Yamakado
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshitaka Inaba
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshihisa Kodama
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Takuji Yamagami
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Miyuki Sone
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hirokazu Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yoshihiro Okumura
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Takayoshi Shinya
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Hiroaki Kurihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Susumu Kanazawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideo Gobara.

Ethics declarations

Grants

Grant-in-Aid from the Japanese Ministry of Health, Labour, and Welfare.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Ethical statement

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Conflict of interest

The authors declare that they have no conflict of interest.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gobara, H., Arai, Y., Kobayashi, T. et al. Percutaneous radiofrequency ablation for patients with malignant lung tumors: a phase II prospective multicenter study (JIVROSG-0702). Jpn J Radiol 34, 556–563 (2016). https://doi.org/10.1007/s11604-016-0557-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11604-016-0557-z

Keywords

Search

Navigation